Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 study of RECCE 327.

Trial Profile

A phase 1 study of RECCE 327.

Phase of Trial: Phase I

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs RECCE 327 (Primary)
  • Indications Diarrhoea; Peptic ulcer; Sepsis
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Mar 2018 New trial record
    • 08 Mar 2018 According to a Recce Pharmaceuticals media release, company has planned a meeting with the US FDA to discuss the unique technology and regulatory pathway for RECCE 327 in May 2018, along with a discussion on this Phase I Clinical Trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top